Stockreport

Disc teases potential NDA for rare skin disorder drug [Yahoo! Finance]

CLINUVEL PHARMS LTD S/ADR  (CLVLY) 
NASDAQ:AMEX Investor Relations: clinuvel.com/investors
PDF Following an end of Phase II meeting, the FDA indicated support for an accelerated approval application based on existing clinical data, with the upcoming Phase III tri [Read more]